Is ascendis health a good investment?
If you are looking for stocks with good return, Ascendis Health Limited stock can be a bad, high-risk 1-year investment option. Ascendis Health Limited real time quote is equal to 96.000 ZAR at 2021-12-02, but your current investment may be devalued in the future.
What does ascendis pharma do?
We are a dynamic, growing biopharma company with offices in Denmark, Germany and the United States. We’re advancing programs both in endocrinology, where we have three rare disease product candidates in clinical development, and in oncology, where we are building a pipeline of candidates.
Where is ascendis Pharma located?
Copenhagen, Denmark
Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform. We are headquartered in Copenhagen, Denmark and are publicly traded, following an initial public offering in 2015 (Nasdaq: ASND). We have employees working across the globe to improve patients’ lives.
What is TransCon technology?
TransCon is an innovative technology platform for drug development. It combines known biology with the benefits of prodrug and sustained-release technologies to potentially optimize therapeutic effect. This could mean enhancing efficacy, improving tolerability and convenience, or reducing caregiver burden.
Is ascendis a buy?
A summary for the Ascendis Health Ltd stock. Signals range from Strong Buy, Buy, Neutral, Sell to Strong Sell….Settings.
| Name | Value | Action |
|---|---|---|
| RSI(14) | 48.567 | Neutral |
| STOCH(9,6) | 62.500 | Buy |
| STOCHRSI(14) | 32.297 | Sell |
| Williams %R | -50.000 | Neutral |
How many employees does ascendis Pharma have?
Compare ASND With Other Stocks
| Ascendis Pharma Annual Number of Employees | |
|---|---|
| 2020 | 482 |
| 2019 | 330 |
| 2018 | 216 |
| 2017 | 137 |
What is TransCon ascendis?
About TransCon™ Technologies. TransCon refers to “transient conjugation.” Ascendis Pharma’s proprietary TransCon platform is an innovative technology used to create new therapies that are designed to potentially optimize therapeutic effect, including efficacy, safety, and dosing frequency.
Will aveng share price recover?
But the company is making a comeback, turning its first annual profit since 2014, in the year ended 30 June 2021. However, its share price is yet to recover and is currently trading at 5 cents, a recovery from 4 cents earlier this week. He added that sentiment needed to change for the company’s share price to improve.
Why did Ascendis share price jump 9% Wednesday morning?
The group’s share price jumped by 9% on Wednesday morning after the announcement. In the past five years, the Ascendis’ share price plummeted by more than 97%, following a raft of debt-funded acquisitions between 2016 and 2017.
Who is Ascendis health’s new chief executive?
Ascendis Health chairman Andrew Marshall said: “Mark has held senior leadership positions in investment banking, the pharmaceutical industry and the retail sector, and has a strong track record in strategic, operational and financial management in large listed and unlisted companies.
What is Ascendis health doing with its debt?
Johannesburg – Ascendis Health (JSE: ASC) has concluded a final agreement with its participating senior lenders for the implementation of the group recapitalisation transaction to settle outstanding debt of approximately €444 million (R7.7 billion).
What brands does Ascendis own?
Ascendis owns brands such as Nimue skin products, Vitaforce supplements and pet products like Triworm, across its consumer, pet and pharmaceutical portfolios.